Compare ACFN & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACFN | MDAI |
|---|---|---|
| Founded | 1986 | 2013 |
| Country | United States | United States |
| Employees | 26 | 78 |
| Industry | Military/Government/Technical | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 39.6M |
| IPO Year | N/A | N/A |
| Metric | ACFN | MDAI |
|---|---|---|
| Price | $17.23 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.25 |
| AVG Volume (30 Days) | 23.2K | ★ 726.9K |
| Earning Date | 03-05-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $63.80 |
| P/E Ratio | $6.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.42 | $1.11 |
| 52 Week High | $33.00 | $3.21 |
| Indicator | ACFN | MDAI |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 53.48 |
| Support Level | $16.12 | $1.48 |
| Resistance Level | $17.20 | $1.76 |
| Average True Range (ATR) | 1.29 | 0.15 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 5.38 | 58.44 |
Acorn Energy Inc is a holding company that focuses on technology-driven solutions for energy infrastructure asset management. It operates through two segments namely, the PG segment and the CP segment. PG segment provides wireless remote monitoring and control systems and services for critical assets as well as Internet of Things applications which account for the majority of the revenue. CP segment is engaged in providing remote monitoring of cathodic protection systems on gas pipelines for gas utilities and pipeline companies.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.